3 active not recruiting, 2 recruiting. 4 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 2, Recruiting 2 |
| Not applicable | 1 | Active not recruiting 1 |
Follow Metastatic Bladder Carcinoma: new trials by email Literature Review of Metastatic Bladder Carcinoma trials Research Report on Metastatic Bladder Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Education and Navigation Support Tool to Improve Participation in Care Coordination Among Patients With Locally Advanced, Metastatic and Unresectable Bladder Cancer and Their Caregivers Assessment of Distress, Consultation Visit, Nutritional Assessment - Locally Advanced Bladder Carcinoma, Metastatic Bladder Carcinoma | Not applicable | Active not recruiting | Roswell Park Cancer Institute | 12 | 2024-01-12 | 2026-08-25 |
| Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology Biospecimen Collection, Computed Tomography, Enfortumab Vedotin - Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma | Phase 2 | Recruiting | Emory University | 25 | 2023-09-26 | 2026-07-29 |
| Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Ipilimumab, Nivolumab, Tocilizumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 35 | 2021-09-23 | 2026-09-16 |
| Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Advanced Bladder Carcinoma, Advanced Genitourinary System Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 60 | 2020-11-03 | 2026-06-11 |
| Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors Biospecimen Collection, Bone Scan, Cabozantinib S-malate - Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 314 | 2019-05-13 | 2026-10-30 |
Urinary Bladder Neoplasms (5) · Urachal adenocarcinoma (2) · Ureteral Neoplasms (2) · Urethral Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Lung Neoplasms (1) · Melanoma (1) · Penile Neoplasms (1) · Prostatic Neoplasms (1) · Urogenital Neoplasms (1)
Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Male Urogenital Diseases (5) · Neoplasms (5) · Neoplasms by Site (5) · Urinary Bladder Diseases (5) · Urogenital Diseases (5) · Urologic Diseases (5) · Urologic Neoplasms (5) · Urogenital Neoplasms (4) · Neoplasms by Histologic Type (2) · Ureteral Diseases (2) · Urethral Diseases (2) · Adenocarcinoma (1) · Bronchial Neoplasms (1)
Magnetic Resonance Spectroscopy (3) · Specimen Handling (3) · CTLA-4 Antigen (2) · Ipilimumab (2) · Nivolumab (2) · Biopsy (1) · Disulfides (1) · Immunoglobulin G (1) · Nutrition Assessment (1) · Palliative Care (1) · cabozantinib (1) · enfortumab vedotin (1) · olaparib (1) · pembrolizumab (1) · tocilizumab (1)
National Cancer Institute (NCI) (2) · Emory University (1) · M.D. Anderson Cancer Center (1) · Roswell Park Cancer Institute (1)
United States (5) · Puerto Rico (1)
Andrea B Apolo (2) · Jacqueline Brown, MD (1) · Rodabe Amaria, MD (1) · Saby George, MD (1)
PMID 35031545, PMID 35537412, PMID 37328287
P30CA138292 (1), U10CA180821 (1), ZIABC011078 (1)